Management of Nexplanon (Etonogestrel Subdermal Implant)
Nexplanon requires no routine follow-up visits after insertion, and patients should be counseled extensively about bleeding irregularities before insertion, as these are the primary reason for discontinuation but are not medically harmful. 1
Pre-Insertion Counseling
Comprehensive counseling before insertion is critical to reduce discontinuation rates. Patients must understand:
- Bleeding pattern changes are expected and not harmful: 22% will experience amenorrhea, 34% infrequent spotting, 7% frequent bleeding, and 18% prolonged bleeding, especially during the first year 1
- Enhanced counseling about expected bleeding patterns has been shown to reduce discontinuation in clinical trials 1
- Nexplanon does not protect against STDs or HIV 2
- The implant is effective for up to 5 years (recently updated from 3 years) 2
- Fertility returns rapidly after removal—pregnancies can occur as early as 7-14 days post-removal 2
Insertion Technique
- Mandatory training is required before performing insertions 3
- Insert subdermally on the inner side of the non-dominant upper arm 2, 4
- Mean insertion time is approximately 28 seconds 2
- The implant must be palpable immediately after insertion—if not palpable, it was likely not inserted correctly 2
- Patients should be advised to contact their provider immediately if they cannot palpate the implant at any time 2
Follow-Up Management
No routine follow-up visit is required after insertion 1. However, advise patients to return:
- At any time to discuss side effects or concerns
- If they want to change methods
- When it's time for removal or replacement (at 5 years)
At opportunistic visits, assess:
- Patient satisfaction with the method
- Changes in health status or medications that would make the implant inappropriate (U.S. MEC category 3 or 4 conditions)
- Weight changes if the patient has concerns 1
Management of Bleeding Irregularities
For Irregular Bleeding (Spotting, Light Bleeding, or Heavy/Prolonged Bleeding)
First, rule out underlying pathology if clinically indicated:
- Drug interactions
- STDs
- Pregnancy
- New uterine pathology (polyps, fibroids) 1
If no underlying problem is found and the patient desires treatment:
- NSAIDs for 5-7 days (celecoxib 200 mg daily or mefenamic acid 500 mg three times daily have shown efficacy) 1
- Hormonal treatment for 10-20 days (if medically eligible): low-dose combined oral contraceptives or estrogen 1
- Doxycycline may be considered (reassurance plus doxycycline is associated with lower removal rates than reassurance alone) 5
Important caveat: Evidence for treatment of bleeding with etonogestrel implants specifically is limited. Studies showing benefit of celecoxib and mefenamic acid were small, and evidence for other treatments is primarily from levonorgestrel implant users 1
If bleeding persists and is unacceptable to the patient, counsel about alternative methods and offer another method if desired 1
For Amenorrhea
Amenorrhea requires no medical treatment—provide reassurance 1
- If bleeding pattern changes abruptly to amenorrhea, consider ruling out pregnancy if clinically indicated
- If amenorrhea persists and is unacceptable to the patient, counsel about alternative methods 1
Removal
- Must be removed by the end of 5 years 2
- Can be removed at any time if the patient desires 2
- A new implant can be inserted immediately after removal if continued contraception is desired 2
- Start another contraceptive method immediately after removal if pregnancy is not desired, as ovulation can return within one week 2
Difficult Removals
- Most removals are straightforward office procedures 4
- If the implant is non-palpable, deep, or associated with pain, consider referral to a specialist 6
- Ultrasound imaging may be needed for localization 6
- Multidisciplinary approach involving peripheral nerve experts may be necessary if neurovascular injury is suspected 6
- Surgical removal is rarely needed (0.14% in one large monitoring program) 3
Common Pitfalls to Avoid
- Failing to counsel adequately about bleeding changes before insertion—this is the most common reason for discontinuation 7, 8
- Not confirming the implant is palpable immediately after insertion—non-palpable implants indicate incorrect insertion 2
- Scheduling unnecessary routine follow-up visits—these are not required and create barriers to access 1
- Treating amenorrhea as a problem—reassure patients this is normal and not harmful 1
- Not offering immediate method switching when bleeding is unacceptable to the patient despite reassurance and treatment 1
Special Considerations
- BMI is not a contraindication: The implant is effective across all BMI ranges, though non-obese women may report more side effects 8
- MRI safe: Nexplanon can be safely scanned 2
- Alternative insertion sites (e.g., scapular region) have been described for patients at risk of self-removal but are not standard practice 9